Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 10/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 5/20 | 0.32 |
| ▸ | CALML3 | P27482 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SDHA | P31040 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7078359 | 0.85 | MAOA (0.35) | MAOAGRM2BTKMAOBCALML3 | |
| SCHEMBL7077034 | 0.83 | MAOA (0.34) | MAOAGRM2BTKMAOBCALML3 | |
| SCHEMBL7030515 | 0.81 | MAOA (0.51) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL8517728 | 0.81 | MAOA (0.51) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL7081634 | 0.80 | GRM2 (0.36) | MAOAGRM2 | |
| SCHEMBL7081042 | 0.80 | GRM2 (0.41) | GRM2LMNASIGMAR1 | |
| SCHEMBL4021263 | 0.80 | MAOA (0.52) | MAOAMAOBSIGMAR1 | |
| SCHEMBL5237085 | 0.79 | MAOA (0.50) | MAOAMAOB | |
| SCHEMBL5833710 | 0.79 | MAOA (0.49) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL7210278 | 0.77 | MAOA (0.44) | MAOAMAOBCALML3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | MAOA 1654/4885GRM2 3844/4885BTK 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.